PMID- 15147037
OWN - NLM
STAT- MEDLINE
DCOM- 20040702
LR  - 20210103
IS  - 0914-7470 (Print)
IS  - 0914-7470 (Linking)
VI  - 16
IP  - 4
DP  - 2003 Dec
TI  - Dendritic cell-based combined immunotherapy with autologous tumor-pulsed 
      dendritic cell vaccine and activated T cells for cancer patients: rationale, 
      current progress, and perspectives.
PG  - 175-82
AB  - Effective adoptive cancer immunotherapy depends on an ability to generate 
      tumor-antigen-presenting cells and tumor-reactive effector lymphocytes and to 
      deliver these effector cells to the tumor. Dendritic cells (DCs) are the most 
      potent antigen-presenting cells, capable of sensitizing T cells to new and recall 
      antigens. Many studies have shown that tumors express unique proteins that can be 
      loaded on DCs to trigger an immune response. The current experimental and 
      clinical statuses of adoptive transfer of tumor antigen-pulsed DCs and 
      vaccine-primed activated T cells are summarized herein. Clinical trials of 
      antigen-pulsed DCs have been conducted in patients with various types of cancer, 
      including non-Hodgkin lymphoma, multiple myeloma, prostate cancer, renal cell 
      carcinoma, malignant melanoma, colorectal cancer, and non-small cell lung cancer. 
      These studies have shown that antigen-loaded DC vaccination is safe and promising 
      for the treatment of cancer. In addition, tumor vaccine-primed T cells have been 
      shown to induce antitumor activity in vivo. Several clinical studies are being 
      conducted on the use of vaccine-primed T cells such as tumor-drainage lymph node. 
      It is reasonable to consider using both tumor antigen-pulsed DCs and 
      vaccine-primed lymphocytes as adjuvants. We are now investigating the use of 
      autologous whole tumor antigen-pulsed DCs and the DC vaccine-primed activated 
      lymphocytes in patients with multiple metastasis of solid tumors.
FAU - Morisaki, Takashi
AU  - Morisaki T
AD  - Department of Cancer Therapy and Research, Station for Collaborative Research, 
      Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, 
      Higashi-ku, Fukuoka 812-8582, Japan.
FAU - Matsumoto, Kotaro
AU  - Matsumoto K
FAU - Onishi, Hideya
AU  - Onishi H
FAU - Kuroki, Hideo
AU  - Kuroki H
FAU - Baba, Eishi
AU  - Baba E
FAU - Tasaki, Akira
AU  - Tasaki A
FAU - Kubo, Makoto
AU  - Kubo M
FAU - Nakamura, Mitsunari
AU  - Nakamura M
FAU - Inaba, Syoichi
AU  - Inaba S
FAU - Yamaguchi, Koji
AU  - Yamaguchi K
FAU - Tanaka, Masao
AU  - Tanaka M
FAU - Katano, Mitsuo
AU  - Katano M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Hum Cell
JT  - Human cell
JID - 8912329
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/immunology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*transplantation
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods/trends
MH  - Neoplasm Metastasis/therapy
MH  - Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/immunology/*transplantation
MH  - Transplantation, Autologous
RF  - 49
EDAT- 2004/05/19 05:00
MHDA- 2004/07/03 05:00
CRDT- 2004/05/19 05:00
PHST- 2004/05/19 05:00 [pubmed]
PHST- 2004/07/03 05:00 [medline]
PHST- 2004/05/19 05:00 [entrez]
AID - 10.1111/j.1749-0774.2003.tb00151.x [doi]
PST - ppublish
SO  - Hum Cell. 2003 Dec;16(4):175-82. doi: 10.1111/j.1749-0774.2003.tb00151.x.